Drug Approval | November 19, 2022
Strides receives USFDA approval for Potassium Chloride Oral Solution
The approval further strengthens the Potassium Chloride franchise for the company.
The approval further strengthens the Potassium Chloride franchise for the company.
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
Subscribe To Our Newsletter & Stay Updated
